FREE CONSULTATION 24/7   800.404.9281  504.286.2022 
Van Robichaux
Trial Attorney
Renee Robichaux
Attorney At Law

On August 12th the FDA announced that starting December 31, 2005, thousands of Accutane users, plus the doctors who prescribe it and stores that sell it, must enroll in a national registry that ensures they understand all the drug’s risks, and take special steps to avoid the most notorious one, Accutane-damaged pregnancies.

Free Accutane Case Evaluation If a woman becomes pregnant while taking the acne drug, her baby can suffer severe brain and heart defects, mental retardation and other abnormalities. The drug may also trigger or worsen depression or suicidal thoughts, according to a warning on the pills’ label that the FDA strengthened Friday and that patients are to receive as part of the new program.

Under iPLEDGE, every patient, man or woman, must enroll in a computerized registry starting December 31st to receive Accutane or a generic version of the drug isotretinoin. Doctors, drugstores and wholesalers must also register.

All patients seeking a prescription for Accutane must sign a document informing them of all of Accutane’s side effects, agree to monthly doctor visits for refills and agree not to share the pills with anyone. The doctor registers each patient into the iPLEDGE database, giving them a special identifying code number and writes the prescription.

Women of childbearing age must undergo additional steps including two tests to ensure that they are not currently pregnant and monthly pregnancy testing (by a physician) before each refill. These women must also agree to use two forms of birth control while using Accutane and must self-register on iPLEDGE, in addition to the doctor’s registration, to report what type of birth control they are using.

Pharmacists must check the database before filling a prescription. Accutane maker Hoffman-LaRoche and generic manufacturers will monitor drugstores and wholesalers and are supposed to cut off violators sales supplies.

The registry actually opens August 22nd to give users time to learn how it works before it becomes mandatory. On that date, patients may enroll at www.ipledgeprogram.com or by phone at 1-866-495-0654. (AP Medical Writer Lauran Neergaard)

 

Free Case Evaluation

General Information
First Name
Last Name
City
Zip Code
State
Country
Primary Phone
Alternate Phone
E-Mail Address
Accutane Use
Date you last used Accutane:
Medications Used
Accutane
Generic Accutane : Amnesteem, Claravis, and/or Sotret.
Diagnosis
Inflammatory Bowel Disease
Ulcerative Colitis
Crohn's Disease
Other (Please Explain)
Approximately what year was the diagnosis by a medical professional?
Please describe the nature and extent of your injuries resulting from your use of Accutane:
Questions / Comments
 
I have read and understand the Terms & Conditions Below.

Send Request
Terms & Conditions
Please be advised we do not and cannot represent you until we have had an opportunity to evaluate your potential claim. Until such time as we have a signed contract of representation from you, we do not represent you in any claim Be advised that the statute of limitations on your claim may have already expired and, if it has not, each day that passes brings you closer to the expiration of the statute of limitations. Thus, you need to act immediately in filling out the above questionnaire. We do not represent you until we have received a fully executed fee agreement.

Thank You! Thank you for your recent inquiry. I, or a member of my staff will contact you by e-mail or telephone to obtain further details.

We will call or email you in the next 30 minutes to discuss your case.

Sorry, There was a problem sending your request. Click the button above to send me an email at info@robichauxlaw.com. I, or a member of my staff will contact you by e-mail or telephone to obtain further details of your Accutane ingestion.



6001 Stars and Stripes Blvd.
Suite 230
New Orleans, LA 70126
Lakefront Airport
800.404.9281
504.286.2022 info@robichauxlaw.com
Google Plus Yelp Avvo Linked In Facebook Twitter Email